



in agreement with

ALABAMA
STATE ASSOCIATION

UAB MEDICINE

The University of Alabama at Birmingham

**The Alabama Executive
Council 2021-22 State
Program Initiative**



**For more information about
Alabama FCCLA, visit our
website
[Home - Alabama FCCLA](#)**

Contact us

Alabama FCCLA
P.O. Box 302101
Montgomery, AL 36130-2101
334-694-4991
State Adviser: Theresa Long

*Bake to
Make
Us Covid
Safe*

The fund was established in March, 2020 to support clinical and laboratory research at UAB meant to save lives, understand the disease, and find treatment. Due to the generosity of business leaders in Birmingham and Montgomery, we quickly raised \$1.1million. Interested applicants were asked to urgently consider how they could contribute to treating a never-before-seen virus. Within 30 days, 14 of the 52 applications had been selected for funding – one of the fastest turn-around times to date.

Additional philanthropic funding is to needed to help support our scientist who are actively working to repurpose existing drugs and to develop new novel drugs to treat coronavirus including acute and long-term effects of COVID 19.

Gifts can be made online at <https://go.uab.edu/COVIDResearchFCCLA> and checks should be made payable to UAB COVID Research Fund and mailed to the following:

UAB Gift Records
AB 1230
1720 2nd Avenue South
Birmingham, AL 35294-0112

Checks should note that the gift is a part of the AlaFCCLA campaign.

Bake to Make Us *Covid Safe* **ROUND 1**

- Early identification and treatment of cytokine storm syndrome in COVID-19
- Defining serologic and neutralizing humoral immunity to COVID-19
- Human lung tissue model of SARS-CoV-2 infection to monitor treatment response
- HelpBeatCOVID19: Crowdsourced COVID-19 Symptom Tracker
- Establishment of a biospecimen repository to enable SARS[1]CoV-2/COVID-19 research at UAB
- SARS-CoV-2 interventions for mitigating COVID-19
- Baseline use of renin-angiotensin-aldosterone system (RAAS) inhibitors and the risk of severe novel coronavirus infection (COVID-19)
- Development of a rapid and scalable COVID-19 antibody epitope mapping platform by phage display
- Optimization of SARS-CoV-2 diagnostic testing throughput and prognostic significance
- Fluorescent cell-based reporter platform for detecting SARS[1]CoV2 infection
- Targeting nsp1 of SARS-CoV-2 for antiviral development
- Development of SARS-2 recombinant proteins for diagnostics, vaccine testing and research
- An animal model of COVID-19 pathogenesis and treatment
- Inhalational bitter taste receptors agonists for treatment of SARS-COV-2

ROUND 2

- Clonal diversity of human antibodies to SARS-CoV-2 S-protein
- Glucocorticoid treatment of COVID-19 cytokine storm syndrome
- Therapeutics targeting COVID-19 entry into pulmonary epithelial cells
- Immunotyping COVID-related acute respiratory distress syndrome
- Circulating microbiota and microbial endotoxin drive uncontrolled immune activation of blood monocytes in COVID-19
- Development of a tri-specific neutralizing antibody for the treatment of SARS-CoV-2 infection
- Individual- and area-level risk factors for COVID-19 disparities in the Deep South
- Exploratory study of the effect of tranexamic acid treatment on the progression of COVID-19 in outpatients
- Molecular mechanisms underlying the pathogenesis of acute respiratory distress syndrome in critically ill SARS-CoV-2-infected patients
- Neutrophils as a driving mechanism of acute respiratory distress syndrome and death in COVID-19 patient



ALABAMA
STATE ASSOCIATION

*All funds raised will go to COVID 19 Clinical and Laboratory Research
Fund at UAB*

Information provided by UAB